PagerDuty's stock is up following 19% jump in revenue
By Jon Swartz
PagerDuty Inc.'s stock inched higher in extended trading Thursday after the cloud-computing company reported quarterly results that breezed past analysts' revenue and earnings estimates.
"We continued to build on our momentum in the enterprise market. We helped companies manage critical work and the way they operate," PagerDuty Chief Financial Officer Howard Wilson said in an interview.
PagerDuty (PD) posted a fiscal second-quarter net loss of $22.6 million, or 26 cents a share, compared with a net loss of $38.6 million, or 44 cents a share, in the year-ago quarter. Adjusted earnings were 19 cents a share.
Revenue jumped 19% to $107.6 million from $90.25 million a year ago.
Analysts surveyed by FactSet had expected on average net income of 11 cents a share on revenue of $104.5 million.
The company provided fiscal third-quarter revenue guidance of between $106.5 million and $108.5 million. Analysts polled by FactSet are forecasting $107.3 million.
Shares of PagerDuty have slid 3% this year, while the broader S&P 500 index SPX has increased 17%.
-Jon Swartz
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
08-31-23 1610ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks